PLoS Medicine:子宫内膜癌可能与HAND2甲基化有关

2013-11-18 佚名 生物通

来自英国伦敦大学学院妇女癌症部的研究人员在11月12日的PLOS Medicine杂志上发表了一项最新研究:发现HAND2基因是子宫内膜癌中的一种差异甲基化热点,这个基因的表观遗传学修饰在子宫内膜癌的发展中起着关键的作用。 作为一种能够引起全球13%死亡人数的疾病,癌症能够在人体的任何地方发生,但是所有癌症都有这样的特征:不受控制的细胞生长和细胞分化减少。遗传改变——在特定基因中的核苷酸序列的变

来自英国伦敦大学学院妇女癌症部的研究人员在11月12日的PLOS Medicine杂志上发表了一项最新研究:发现HAND2基因是子宫内膜癌中的一种差异甲基化热点,这个基因的表观遗传学修饰在子宫内膜癌的发展中起着关键的作用。

作为一种能够引起全球13%死亡人数的疾病,癌症能够在人体的任何地方发生,但是所有癌症都有这样的特征:不受控制的细胞生长和细胞分化减少。遗传改变——在特定基因中的核苷酸序列的变化——是这种细胞性状转化和随后的癌症发展(致癌作用)所必需的。【原文下载】

然而,最近的研究表明,表观遗传学修饰——在没有核苷酸序列改变的情况时,基因功能的可逆的、可遗传的改变——也跟致癌作用有关。例如将甲基原子团加到一组称为干细胞多梳蛋白家族靶基因(PCGTs,多梳基因,通过修改它们的DNA或者相关蛋白,控制它们的靶基因的表达)的基因中,是最早用于人类癌症发展的分子改变之一,越来越多的证据表明,PCGTs甲基化是一种癌症的表观遗传学标志


PCGTs甲基化,由年龄和环境因素触发,与癌症的发生、细胞分化减少有关,能够引起易受癌症发展影响的未分化细胞的积累。然而,是否表观遗传修饰在癌症形成中起因果作用,还不明确。研究者调查了参与子宫内膜癌发展的表观遗传学因素。子宫内膜癌的风险(在美国,每年影响将近50000位女性),主要由环境和生活方式的因素决定。尤其是,体内雌激素(一种引起子宫内膜细胞增殖的激素)在功能上主导了孕酮(一种抑制子宫内膜增殖和引起细胞分化的激素)的妇女、肥胖的妇女和做过“仅雌激素替代疗法”的妇女中,这种癌症的风险有所增加。因此,子宫内膜癌是研究是否表观遗传学机制是致癌作用基础的一个理想模型。

来自英国伦敦大学学院妇女癌症部的Martin Widschwendter和合作者在11月12日的PLOS Medicine杂志上发表了一项最新研究,系统地比较了子宫内膜癌和正常子宫内膜的甲基化模式。

研究者收集了分别来自子宫内膜癌和正常子宫内膜的基因组范围的DNA甲基化数据,采用一种称为功能表观遗传学模块(Functional Epigenetic Modules,FEM)的计算方法,将这些信息与人类相互作用组及转录组整合在一起。通过这些分析,研究者将HAND2基因鉴定为子宫内膜癌中的一种差异甲基化热点。HAND2是一个孕酮调节的干细胞PCGT基因,它编码一个在子宫内膜基质中表达的转录因子,抑制一种生长因子——这种生长因子能够介导雌激素在子宫内膜上皮组织中的增长诱导效应——的产生。因此,研究者推断,HAND2基因的表观遗传学修饰在子宫内膜癌的发展中起着关键的作用。HAND2基因在健康的子宫内膜中很活跃,在那里它对抗雌激素的生长诱导作用。相反地,在超过90%的子宫内膜癌患者中,这个基因已经发生了甲基化。

研究者发现,相比较正常子宫内膜,在癌变前的子宫内膜病变(易患癌症的、形态异常的组织)中,HAND2甲基化已经出现了增加,一个高水平的甲基化能够预测对孕酮治疗(阻止一些变肿瘤前的子宫内膜病变的生长)的一个较差反应。

而且,通过对从绝经后子宫出血妇女中收集的子宫内膜分泌物中的HAND2甲基化进行分析,研究者精确地鉴定出早期癌症患者。最后,研究者通过一个HAND2基因被特定敲除的小鼠模型,研究了HAND2沉默的功能相关性。带领这项研究的Widschwendter称:“我们的研究提供了明确的证据表明,不仅遗传学改变能够触发和引起癌症,表观遗传学改变也是癌症启动的一步。”子宫内膜癌是最常见的妇科癌症,在一个年龄更大的和更肥胖的女性群体中,它的发生率持续上升。作者指出,HAND2甲基化“能够应用于分诊那些出现了绝经后子宫出血(当前,大约90%有这种症状的女性,必须经过子宫内膜活检,才能得到一个明确的无癌诊断)的女性,能够进一步作为一项检测来早期发现乃至预测子宫内膜癌的风险和对预防治疗做出反应”。

原文出处:

Allison Jones; Andrew E. Teschendorff; Quanxi Li; Jane D. Hayward; Athilakshmi Kannan; Tim Mould; James West; Michal Zikan;David Cibula; Heidi Fiegl; Shih-Han Lee; Elisabeth Wik; Richard Hadwin; Rupali Arora; Charlotte Lemech;Henna Turunen; Päivi Pakarinen;Ian J. Jacobs; Helga B. Salvesen; Milan K. Bagchi;Indrani C. Bagchi;Martin Widschwendter. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development.PLOS MED.Nov 12, 2013DOI: 10.1371/journal.pmed.1001551【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773456, encodeId=86cd1e73456c4, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Apr 06 00:04:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858579, encodeId=390518585e9c3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 25 21:04:00 CST 2014, time=2014-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577409, encodeId=8ecc15e740965, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606052, encodeId=ad5f160605222, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708296, encodeId=8ba01e0829661, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Nov 04 08:04:00 CST 2014, time=2014-11-04, status=1, ipAttribution=)]
    2014-04-06 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773456, encodeId=86cd1e73456c4, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Apr 06 00:04:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858579, encodeId=390518585e9c3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 25 21:04:00 CST 2014, time=2014-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577409, encodeId=8ecc15e740965, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606052, encodeId=ad5f160605222, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708296, encodeId=8ba01e0829661, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Nov 04 08:04:00 CST 2014, time=2014-11-04, status=1, ipAttribution=)]
    2014-05-25 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773456, encodeId=86cd1e73456c4, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Apr 06 00:04:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858579, encodeId=390518585e9c3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 25 21:04:00 CST 2014, time=2014-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577409, encodeId=8ecc15e740965, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606052, encodeId=ad5f160605222, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708296, encodeId=8ba01e0829661, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Nov 04 08:04:00 CST 2014, time=2014-11-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773456, encodeId=86cd1e73456c4, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Apr 06 00:04:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858579, encodeId=390518585e9c3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 25 21:04:00 CST 2014, time=2014-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577409, encodeId=8ecc15e740965, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606052, encodeId=ad5f160605222, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708296, encodeId=8ba01e0829661, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Nov 04 08:04:00 CST 2014, time=2014-11-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773456, encodeId=86cd1e73456c4, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Apr 06 00:04:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858579, encodeId=390518585e9c3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 25 21:04:00 CST 2014, time=2014-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577409, encodeId=8ecc15e740965, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606052, encodeId=ad5f160605222, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 20 04:04:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708296, encodeId=8ba01e0829661, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Nov 04 08:04:00 CST 2014, time=2014-11-04, status=1, ipAttribution=)]

相关资讯

宫腔镜诊断子宫内膜癌优于分段诊刮

       近日,广西医科大学第七附属医院研究人员发表论文,旨在探讨宫腔镜检查对子宫内膜癌的诊断价值,以及是否增加腹腔冲洗液细胞学阳性率。研究指出,宫腔镜检查诊断子宫内膜癌准确性优于单纯分段诊刮,并且不增加腹腔冲洗液阳性率。腹腔冲洗液阳性率与宫腔病灶范围大小有关。该文发表在2012年第05期《实用妇产科杂志》上。   研究人员回顾性分析在本院行手术治疗后病理检查确诊为子宫内膜癌患

GYNECOL ONCOL :抗糖尿病药物与子宫内膜癌风险无关

  瑞士一项研究表明,使用二甲双胍和其他抗糖尿病药物与子宫内膜癌患病风险无关。该研究论文3月20日在线发表于《妇科肿瘤学》(Gynecol Oncol)杂志。   该研究是一项病例对照研究,利用英国全科医学研究数据库(GPRD)探索了二甲双胍和其他抗糖尿病药物与子宫内膜癌风险的关联。研究对象为偶发性子宫内膜癌患者和与之匹配的对照者。   结果,研究共纳入2554例子宫内膜

AJE:女性30岁后生育会降低子宫内膜癌风险

南加州大学Keck医学院的一项研究显示,那些最后一次生育在25岁以下的女性相比,最后一次生育在40岁或者更晚会使子宫内膜癌的风险下降了44%。该研究的主要负责人Veronica Wendy Setiawan博士发现女性30岁后,最后一次生育的年龄每延后五年,患该肿瘤的风险下降将近13%。因此该研究能显著地反映出较晚的最后生育年龄是一个保护女性免受子宫内膜癌侵害的重要因素。 该研究检测了来自四个定

ECO2013:过去60年的数据显示儿时的肥胖和身高指数与成人子宫内膜癌相关

发布在5月12日开始的利维浦欧洲肥胖会议(ECO)上的一项新的研究显示儿童期的肥胖和身高指数可能与成人期子宫内膜癌相关。这项研究由哥本哈根大学附属医院预防医学研究院的Julie Aarestrup,Copenhagen, Denmark及其同事完成。欧洲每年新发子宫内膜癌超过90,000例,在女性肿瘤中排名第四。对于成年女性,子宫内膜癌的风险增加与高体质指数(BMI)密切相关,而与身高无明显相关。

JNCI:免疫法或可预测子宫内膜癌预后

L1CAM可预测早期I型子宫内膜癌患者的预后 国际妇产科联合会的(FIGO)分期指出,I期I型的子宫内膜癌患者预后极佳,但是仍有相当多的I期I型的子宫内膜癌患者经历复发,甚至于出现死亡的临床结局。因此,为了寻找更好的针对I期I型的子宫内膜癌患者预后的预测因素,来自于奥地利Innsbruck医科大学的Alain G. Zeimet等设计了相关研究以评价通过免疫组化法所确定的L1

EMCC 2013 :绝经后持续使用雌孕激素可防子宫内膜癌

阿姆斯特丹——欧洲多学科癌症会议上公布的女性健康倡议(WHI)随机安慰剂对照试验的扩展随访结果显示,持续使用雌激素和孕激素可预防绝经后女性发生子宫内膜癌。中位随访13.2年后,雌激素/孕激素联合激素治疗(HT)组的子宫内膜癌发生率比安慰剂组低35%[风险比(HR) 0.65;P = 0.007]。HT组和安慰剂组分别共有66例和95例女性发生子宫内膜癌,年发生率分别为0.06%和0.10%。 1